Most recent update: Tuesday, January 16, 2018 - 10:37

Bariatric News - Cookies & privacy policy

You are here

Prescribed drugs

Diabetes drugs prescribed 15 times more than obesity drugs

Researchers pointed to a number of barriers to obesity treatment including lack of reimbursement for healthcare providers, limited time during office visits, lack of training in counselling, and competing demands, among others.

Healthcare clinicians prescribe 15 times more anti-diabetes medications than those for obesity, according to research published in the journal Obesity, the scientific journal of The Obesity Society. Although six anti-obesity medications are now approved by the Food and Drug Administration (FDA) for treating obesity when combined with a reduced-calorie diet and increased physical activity, this research points out that only 2% of the eligible 46% of the US adult population is receiving these medications.

“Given the close tie between obesity and type 2 diabetes, treating obesity should be an obvious first step for healthcare providers to prevent and treat diabetes,” said Catherine E Thomas, the lead researcher from Weill Medical College of Cornell University. “By treating obesity, we may be able to decrease the number of patients with type 2 diabetes, among other related diseases and the medications used to treat them. A greater urgency in the treatment of obesity – on the part of clinicians and patients – is essential. We’re talking about prolonged and better quality of life for patients.”

Researchers pointed to a number of barriers to obesity treatment including lack of reimbursement for healthcare providers, limited time during office visits, lack of training in counselling, and competing demands, among others. 

In their study, ‘Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s’, Thomas and colleagues performed a retrospective analysis of 2012 – 2015 data from the IMS Health National Prescription Audit and Xponent databases to examine prescribing trends for anti-diabetes and anti-obesity medications. According to the analysis, the number of prescribed anti-diabetes medications (excluding insulin) was 15 times the number of prescribed anti-obesity medications (Figure 1). Medical specialties prescribing the majority of the anti-obesity medications included family medicine/general practitioners, internal medicine clinicians and endocrinologists.

Figure 1: Prescriptions for anti-diabetes and anti-obesity medications

“By comparing the adoption rate of new anti-obesity medications to the considerably faster rate for new diabetes medications, this new research provides an important snapshot of the problem,” said Ted Kyle, founder of ConscienHealth in a commentary accompanying the research.

According to the commentary by Kyle, future research should aim to better quantify the benefit of obesity medications in real clinical settings as measured by patient outcomes. Additionally, a better understanding of the systematic barriers to adoption of obesity pharmacotherapy is necessary.

“Obesity is a serious disease that is not getting serious treatment,” said Dr Charles Billington, past president and spokesperson for The Obesity Society and Director of Medical Weight Management at the University of Minnesota. “We are missing the opportunity among patients with serious obesity-related illness to provide the full range of proven, safe and effective therapies. It’s time to start treating people with obesity as we would others with chronic diseases – with compassion and access to evidence-based care in a clinical setting.”

The authors of this research were given access to the prescription databases through a partnership with Vivus.

To access the paper, please click here

To access the commentary, please click here

Want more stories like this? Subscribe to Bariatric News!

Bariatric News
Keep up to date! Get the latest news in your inbox. NOTE: Bariatric News WILL NOT pass on your details to 3rd parties. However, you may receive ‘marketing emails’ sent by us on behalf of 3rd parties.